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Abstract
The treatment of inflammatory bowel disease (IBD) has undergone a major
paradigm shift in the last two decades with the introduction of biological drugs.
Tumoral necrosis factor (TNF) antagonists were the first monoclonal antibodies
available for treatment of IBD. New emerging concepts as early initiation of treat-
ment during the “opportunity window,” and “treat to target” with a tight control
strategy have contributed to optimum utilization of these drugs allowing better
long-term outcomes for treated patients. This chapter aims to review all current
pivotal data regarding efficacy and safety of infliximab, adalimumab, certolizumab
pegol, and golimumab, as long as real life experience with these agents. Compara-
tive efficacy among anti-TNF agents and the role of therapeutic drug monitoring in
the management of IBD will also be discussed. Last, the authors present future
perspectives with the drugs and position anti-TNF agents as viable therapeutic
options in the current IBD therapeutic armamentarium.
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1. Introduction
The treatment of inflammatory bowel disease (IBD) has remained a challenge
for physicians involved in disease care because of its chronic nature and the impact
on patient’s quality of life. Traditionally, the pharmacological arsenal for the treat-
ment of Crohn’s Disease (CD) includes the aminosalicylates (sulfasalazine,
mesalazine), immunosuppressants (e.g., azathioprine, 6-mercaptopurine, and
methotrexate), corticosteroids (e.g., prednisone, hydrocortisone, methylpredniso-
lone, and budesonide), and antibiotics. This therapeutic armamentarium, regarded
as “conventional,” does not seem to interfere with the natural history of the disease,
while improving the symptoms of many patients [1–3].
In the last two decades, there has been a major paradigm shift in the treatment of
IBD, with the introduction of biological drugs (monoclonal antibodies) [4, 5]. Bio-
logical drugs were the only class of drugs that alter the natural course of the disease,
reducing the risk of hospitalizations, and surgeries [6]. However, insights into the
importance of early and optimized therapy have prompted interest in a ‘treat to
target’ approach to achieve good disease control. This strategy involves treating to
a pre-defined target that is associated with optimal long-term outcomes. Regular
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monitoring of objective measures of disease is required, and treatment is optimized
based on these findings to ensure the target is achieved and maintained.
The natural course of inflammatory bowel disease is characterized by periods of
remission and exacerbation and, over time, patients can develop irreversible damage
such as stenosis and fistulas in Crohn’s disease shortening and lead pipe appearance of
colon in UC. However, it has been shown that early diagnosis with identification of
severity predictors factors [7] and the early initiation of treatment with biological
drugs during the “opportunity window,” where symptoms are mainly derived from
the diseases inflammatory activity in its initial phase, significantly reduces the rate of
surgical complications, such as fistula stenosis in CD, as well as the need for
colectomy in patients with UC who present severe acute colitis or chronic colitis
refractory to corticoid, aminosalicylates, and immunosuppressive therapy [8–10].
The current IBD treatment goals include not only symptoms control, mainly but
also sustained control of inflammation, through the mucosal healing and complica-
tion prevention (fistulae, abscesses, stenoses, dysmotility, and dysplasia), which
may lead to hospitalization, surgery and substantial impact in quality of life [1, 11, 12].
In 2015, the International Organization for the Study of Inflammatory Bowel
Diseases for the Study of Inflammatory Bowel Diseases (IOIBD) published the
Figure 1.
TNF’s mechanisms of action - In the pathophysiology of Crohn’s disease,TNF is produced at high concentrations
by a variety of cell types, presumably induced by endogenous or microbial stimuli. A cascade and network of
cellular responses mediated by TNF are shown in the the diagram.
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selecting therapeutic targets in inflammatory bowel disease (STRIDE), where 28
experts in IBD developed recommendations based on a systematic literature
review and expert opinion proposing the strategy “treat to target” in IBD. In this
publication, the recommended therapeutic targets were clinical remission defined
by improvement in bowel movements and the resolution of the associated rectal
bleeding for UC or abdominal pain for Crohn’s disease. Furthermore, endoscopic
remission with no ulcerations in CD and an endoscopic Mayo score 0-1 in UC should
be confirmed [11].
The “treat to target” strategy defines the therapeutic goals that professionals
should aim for, although it is important to emphasize which treatment strategy
should be adopted in order to achieve the desired outcome. With that purpose, in
2017 the effect of tight control management on Crohn’s disease (CALM) trial was
published, a multicenter phase 3, randomized controlled trial designed to evaluate
the safety and effectiveness of two treatment strategies in patients with CD scaling
to biological therapy based on predefined criteria of treatment failure. The primary
endpoint was the mucosal healing, defined by a CDEIS <4 score and the absence of
deep ulcers at the end of 48 weeks, patients were randomized into two groups: the
“tight control,” where therapy was scaled based on clinical evaluation and bio-
markers (fecal calprotectin and CRP), and the clinical management group, in which
only the symptom assessment was considered. It was observed that a significantly
higher proportion of patients in the “tight control” group reached the primary
endpoint compared to the clinical management group, showing that the escalation
of biological therapy guided by targets in patients with early CD is associated with
better clinical and endoscopic outcomes when there is an association of clinical
evaluation and biomarkers for decision-making [13].
The first group of biological medicines was composed by tumoral necrosis factor
(TNF) antagonists, approved for use in Crohn’s disease patients in 1998. The cur-
rently available anti-TNFs for treatment of CD are infliximab, adalimumab, and
certolizumab pegol (Figure 1).
2. Infliximab (Remicade®)
The infliximab (IFX), a chimeric monoclonal IgG1 antibody, was the first bio-
logical used in CD. In 1997, Targan et al. published a randomized controlled trial
demonstrating the superiority of the drug in inducing clinical remission in moderate
to severe CD compared to placebo. Four groups were defined, involving 108
patients, to receive doses of 5, 10, 20 mg/kg, or placebo. The primary outcome was
clinical response after 4 weeks, defined by a decrease of 70 points, or more in CDAI
score after a single infusion. It was observed that 81% of patients receiving 5 mg/kg,
50% of those who received 10 mg/kg, and 64% receiving 20 mg/kg achieved the
goal, compared to only 17% in the placebo group (p < 0.001). This was the first
comparative, randomized, placebo-controlled trial involving IFX in the treatment
of CD. It is a landmark in biological therapy because it has demonstrated superiority
of this drug over placebo in a single infusion and guided the currently adopted dose
of 5 mg/kg [14]. Subsequently, Present et al. published a longer lasting study with
18 weeks of follow-up involving patients with penetrating CD that had active
fistulas. In addition of the initial dose at week 0, IFX was administered at weeks 2
and 6 in two groups with 5 or 10 mg/kg compared to the placebo group. The
primary endpoint was the 50% reduction in the drainage of fistula, which occurred
in 68, 56, and 26% in the groups 5, 10 mg/kg, and placebo, respectively, with
statistical significance [15].
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With the efficacy of IFX in inducing clinical remission established, in order to
evaluate its efficacy in maintain clinical response in CD, in 2002 the ACCENT I
study was published, the most relevant publication related to IFX in CD; a multi-
center study (US, Europe, and Israel), controlled trial involving 573 patients with
moderate to severe Crohn’s disease (CDAI between 220 and 400). All patients
received a dose of IFX 5 mg/kg and were assessed after 2 weeks. Of these, 325 (58%)
had clinical response (CDAI decrease of 70 points or more at baseline) and were
randomized at week 2 into 03 groups: 5, 10 mg/kg, and placebo. Following treat-
ment regimen suggested by Present et al., doses were administered at weeks 0, 2,
and 6, and subsequently administered every 8 weeks. The primary endpoint was
clinical remission (CDAI <150 points) maintained after 30 and 54 weeks of initiat-
ing therapy. It was observed that those who responded to induction dose had higher
remission rate at weeks 30 and 54. The maintenance of clinical remission rates at
54 weeks were significantly higher in the groups that received IFX 5 and 10 mg/kg
(28.3 and 38.4%, respectively) compared with placebo (13.6%), showing the effec-
tiveness of maintenance therapy with IFX. No statistical significance was observed
in the difference between 5 and 10 mg/kg groups. In addition, in the placebo group,
there was no mucosal healing at week 10, whereas patients receiving IFX in doses of
5 and 10 mg/kg, healing was observed in 31% of cases [16]. Following this line of
reasoning, ACCENT II was published in 2004, a phase III randomized, double-
blind, placebo-controlled study that included 306 patients with penetrating CD
(enterocutaneous and perianal fistula), of which 282 were randomized at week 14
after the induction therapy (weeks 0, 2, and 6) for receiving infusions of 5 mg/kg or
placebo every 8 weeks, aiming to evaluate the loss of IFX response in both groups
after 54 weeks of treatment. It was observed that the time to loss of response was
significantly higher in the IFX group over placebo (>40 weeks vs. 14, p < 0.001),
and after 54 weeks, only 19% of the patients in the placebo group did not have
fistulas in compared to 36% in the IFX group (p = 0.009) [17].
In order to assess the IFX therapy effectiveness in induction and maintenance of
clinical response in moderate to severe UC two phase III placebo-controlled studies
were subsequently published: the ACT I and II. With a total of 364 patients involved
in each study, they were randomized to receive placebo, 5 or 10 mg/kg at weeks 0,
2, and 6, followed by infusions every 8 weeks through weeks 46 (ACT I) and 22
(ACT II). The primary endpoint was to evaluate clinical response (defined as
decrease of three points in Mayo score and, at least, one point in the sub-item for
rectal bleeding) at week 8, having as secondary endpoints the clinical response or
remission after corticosteroid withdrawal and mucosal healing at weeks 8, 30 in
both studies, and at week 54 in ACT I. In this last study, only 37% of patients in
placebo group had clinical response at week 8 versus 69% (p < 0.001) in the
5 mg/kg group and 62% (p < 0.002) in the 10 mg/kg group. In ACT II, 64% of
patients receiving IFX 5 mg/kg and 69% of those who received 10 mg/kg had
clinical response at week 8 compared to 29% of those receiving placebo (p < 0.001
for both comparisons). In both studies, clinical response was more frequently
observed at week 30 among patients who received IFX (p < 0.002 for all
comparisons). In ACT I, after 54 weeks, more patients receiving IFX 5 or 10 mg/kg
(45 and 44%, respectively) showed clinical response compared to placebo (20%,
p< 0.001) [18].
The pivotal studies mentioned consolidated IFX use as induction and main-
tenance therapy in CD and UC. However, in general, the clinical trials inclusion
criteria are too restrictive, restricting the participation of most patients in daily
clinical practice. One of the biggest real-life studies evaluating the effectiveness
of treatment of CD with IFX was published in 2009 by Schnitzler et al. from
Leuven group. Six hundred fourteen patients were evaluated with a median of
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55 months follow-up, in which approximately 11% were primary non-
responders. Of the 547 remaining, 63.3% of patients had sustained clinical
benefit. Treatment was discontinued in 31.7% of cases due to complete remis-
sion, 12.8% due to adverse events, and 21.6% due to loss of response to the drug.
This study demonstrated that good results can be obtained with IFX treatment in
the real world, when the requirements of controlled studies are often not
attained [19].
In order to evaluate the safety profile and long-term repercussions of IFX
treatment based on real life clinical experience, Sandborn et al. published in 2012 a
study involving 492 CD patients treated between 1998 and 2002 at the Mayo Clinic
and followed until 2009. It was shown that approximately 80% of patients showed
clinical response to induction therapy, of which 25% with partial and 75% with
complete response, in agreement with previously reported data [16, 17]. Dose
escalation or shortening of the interval between infusions occurred in approxi-
mately 57% of patients who received maintenance dose with a cumulative proba-
bility of a therapeutic adjustment of 19% in the first year, 57% in 5 years, and 74% in
10 years of follow-up, reflecting that there is a loss of response over time. Note that
10% of the 182 patients who received maintenance therapy, discontinued its use
because of loss of response. The cumulative probability of adverse events was
around 35% in the first year, increasing to 86% after 10 years of therapy. Approxi-
mately 5% of patients developed cancer, with a cumulative probability of 9.1% in
10 years, though it was unclear if this increased incidence of cancer was related to
the CD itself, the use of IFX or because this study was performed at a reference
center with a specific profile of patients. The most common infectious
complications were bacterial infection (intra-abdominal abscesses and pneumonia)
and viral [20].
Long-term studies have demonstrated that, despite its effectiveness, IFX shows
loss of response over time, with frequent need for dose escalation due to their
immunogenicity. Then was raised the possibility of association of anti-TNF with
immunosuppressive agents such as azathioprine (AZA) and 6-mercaptopurine, as
synergists agents. In this context, the SONIC study was published in 2010 evaluat-
ing 508 patients with CD randomized to three different treatment strategies: IFX
monotherapy, AZA monotherapy, or combination therapy with the two drugs.
After 30 weeks of treatment, approximately 57% of patients treated with the com-
bination therapy achieved corticosteroid free clinical remission (primary endpoint),
compared to 44.4% in IFX monotherapy group (p = 0.02) and 30% in AZA
monotherapy group (p < 0.001 for combination therapy; p = 0.006 for IFX).
The mucosal healing rate was also higher in the combination therapy and IFX
monotherapy groups compared to isolated AZA (p < 0.001 and p = 0.02, respec-
tively). The difference between the IFX monotherapy and combination therapy
groups in this outcome was not statistically significant (p = 0.06) [21]. With a
similar study design, the SUCCESS was published in 2014, analyzing 239 patients
with moderate to severe UC who were randomized to treatment with the combina-
tion therapy (IFX + AZA), IFX monotherapy, or AZA alone. Steroid-free clinical
remission at week 16 was achieved by 39.7% of patients treated with the combina-
tion therapy compared to 22.1% in the IFX group (p = 0.017) and 23.7% in the AZA
group (p = 0.032). Similarly, the difference in mucosal healing was only statistically
significant when the combination therapy was compared to AZA monotherapy
(62.8 and 36.8%, respectively, p = 0.001) [22].
The data presented above have reassured that IFX, marketed for over 20 years,
are efficient and have a satisfactory safety profile, being considered as a
first-line biological treatment of IBD, especially in the management of perianal
Crohn’s disease and severe acute colitis. Moreover, it plays an important
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role in the management of extra intestinal manifestations and the prevention
of postoperative recurrence [23].
3. Adalimumab (Humira®)
Adalimumab, a fully humanized monoclonal antibody IgG1, was the second
anti-TNF antibody released for treating IBD. The first paper published on the
efficacy of ADA in induction of remission in CD was the CLASSIC I trial in 2006.
Aiming the assessment of clinical response after 4 weeks of treatment (CDAI <150
points), 299 patients naïve to anti-TNF therapy were randomized to receive,
respectively, at weeks 0 and 2, a dose of ADA 40/20, 80/40, 80/160 mg, or placebo.
The results showed major clinical remission rate at a dose of 160/80 mg (36%)
compared to placebo (12%, p < 0.001). Secondary endpoints were to evaluate the
partial clinical improvement, defined by a decrease of 70 or 100 points in the CDAI.
The first one was obtained with the three therapeutic regimens and the last only by
the 160/80 mg dose, which has defined this regimen as the best option for ADA
induction therapy [24].
In order to establish the efficacy of ADA in maintaining clinical response,
CLASSIC II was subsequently published evaluating 55 patients from the CLASSIC I
who were in clinical that were further randomized to three different treatment
regimens: ADA 40 mg every other week, 40 mg weekly, or placebo until completing
56 weeks. In addition, 204 patients from CLASSIC I who were not in clinical
remission were enrolled in an open label arm to use ADA 40 mg every other week.
The primary endpoint was to evaluate the clinical remission (CDAI <150 points)
among randomized patients and it was observed that 79% of patients receiving ADA
every other week and 83% of those who received ADA weekly were in clinical
remission against 44% in the placebo group (p < 0.05) Among the 204 patients
assigned to treatment with ADA 40 mg every other week, 46% achieved clinical
remission at the end of the 56 weeks. It is noteworthy that this is a study with a low
randomized sample [25].
In order to emphasize the sustained efficacy of ADA in CD therapy, in 2007
Colombel et al. published the CHARM trial, a phase III study involving 854 patients
who initially were subjected to induction with ADA, of which 499 (58%) had initial
clinical response (CDAI decrease in ≥70 basal line) and were randomized to main-
tenance therapy with ADA 40 mg every other week, 40 mg weekly, or placebo with
assess of clinical remission (CDAI <150) after 26 and 56 weeks of therapy. Analyz-
ing the randomized groups, it was noted that clinical remission was significantly
greater in the groups using ADA than to placebo at week 56, with 41% in the group
receiving the drug weekly, 36% in the group receiving every other week, and 12% in
the placebo group (p < 0.001). There was no statistically significance in
the difference observed between the groups treated with ADA, confirming that
the best initial regimen therapy with ADA is 40 mg every other week. It was noted
that the superior results observed in CLASSIC II may be due to the fact that patients
randomized in this study were in clinical remission, while in CHARM patients
with a partial clinical response were included, giving a difference in population of
the two studies, preventing direct comparison between them [26]. Analyzing the
subgroup of patients who had been previous treated with IFX and discontinued
therapy due to loss of response or intolerance it was also observed a higher
remission rate compared to placebo, confirming that ADA therapy is a plausible
alternative in this group of patients.
In order to properly evaluate the effectiveness of ADA as a rescue therapy in
patients with CD who have intolerance or loss of response to IFX, GAIN study was
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further published in 2006. Similarly to CLASSIC I, clinical remission was assessed at
the end of 4 weeks after the randomization of 325 patients to receive induction
therapy (160 and 80 mg at weeks 0 and 2) or placebo. It was observed that 21% of
patients with ADA therapy reached the primary endpoint compared to only 7% in
the placebo group (p < 0.001). This study has demonstrated that ADA is indeed
an alternative for patients with refractory CD or is intolerant to IFX [27].
The therapy with ADA in UC was described later, when, in 2010, ULTRA 1 was
published evaluating the drug efficacy in induction of clinical remission in patients
naive for biological drugs. The study included 390 patients randomized into three
groups to receive ADA in induction regimen with 160/80 mg at weeks 0 and 2,
followed by 40 mg at weeks 4 and 6; 80/40 mg at weeks 0 and 2, followed by 40 mg
every other week and the placebo group. At the end of 8 weeks, approximately 19%
of patients in group 160/80 mg showed clinical remission compared with 9.2% of
patients in the placebo group (p = 0.031), showing modest efficacy of this thera-
peutic regimen in UC patients who failed therapy with corticosteroids and/or
immunosuppressant. The induction regimen with ADA 80/40 mg compared to
placebo did not present statistical significance [28].
To analyze the efficiency in the induction of remission and also the maintenance
of clinical response ULTRA 2 was sequentially published, studying 494 patients
with UC who were initially stratified by prior use or not of anti-TNF alpha and
randomized for induction therapy with ADA 160/80 mg at weeks 0 and 2 followed
by ADA 40 mg every other week or placebo. The primary endpoint was clinical
remission at weeks 8 and 52. Analyzing the group as a whole, there was no statisti-
cally significant difference at week 8, however, at week 52, 17.3% of patients with
ADA achieved clinical remission superior to placebo group (8.5%, p = 0.004). The
superiority was also observed at the end of 52 weeks (12.4 vs. 22%, respectively;
p = 0.029). In the subgroup previously experienced with anti-TNF alpha, a statisti-
cally significant superiority was observed at the end of 52 weeks (10.2% in the ADA
group vs. 3% in the placebo group, p = 0.039) [29].
Even though data in pivotal studies for ADA in UC are not as robust, Tursi et al.
published in 2018 the results of a real-life study involving 102 UC patients demon-
strating drug efficacy and safety more consistently. The primary outcome was the
induction and maintenance of remission, defined by a Mayo score ≤ 2. At 3 months,
54.9% of patients achieved clinical remission and during an average follow-up of
18 months, 56.6% of the patients were in this same situation. Secondarily, clinical
response and mucosal healing was achieved by 89.2 and 76.7% of the patients,
respectively. Only three patients underwent colectomy (two because of primary
therapeutic failure and one for secondary loss) and one patient discontinued treat-
ment due to leukopenia [30].
In relation to real life experience in CD, Loftus et al. recently published the
results of PYRAMID registry, evaluating the efficacy and safety of ADA in patients
naive to biological therapy followed for 6 years. Taking into consideration the
Physician’s Global Assessment (PGA) and clinical remission (Harvey Bradshaw
index <5), 2057 patients were analyzed with an improvement baseline PGA from
7.5 to 3.9 in the first year and 3.3 in the sixth year. The rate of patients in clinical
remission increased from 29 to 68% and 75% after 1 and 6 years, respectively. As
related to adverse events, 11.1% of patients had severe infections and the incidence
of malignancy was relatively low (1.9%) [31].
ADA has demonstrated superiority to placebo for induction and maintenance of
remission in patients with CD and UC. Its subcutaneous administration seems to be
a more convenient approach to patients who prefer to self-administer. It is also
considered a first-line agent in the management of moderate to severe CD and UC
patients refractory to conventional therapy with a satisfactory safety profile.
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4. Certolizumab pegol (Cimzia®)
Certolizumab pegol (CZP), a pegylated humanized Fab fragment of IgG1 was
also studied in CD. Although the initial induction trial did not demonstrate statisti-
cally significant difference in clinical remission after 6 weeks of treatment com-
pared to placebo, PRECISE 2 study was further published assessing maintenance of
clinical response in 213 patients that responded to induction phase with 400 mg at
weeks 0, 2, and 6 and had values of CRP ≥ 10 mg/L (50% of 428 patients with a
reduction in CDAI >100 points after induction phase). These patients were ran-
domized into two groups to receive either 400 mg of CZP or placebo. At the end of
26 weeks of follow-up, 62% of patients treated with the drug maintained clinical
response, showing superiority over placebo (34%, p < 0.001). Second, it was
observed that this superiority was maintained even for patients with CRP
< 10 mg/L after the induction phase [32]. Subsequently, analyzing CD patients
treated with CZP and followed for 7 years, it was seen that it showed a comparable
safety profile to the others anti-TNF drugs [33].
Since chronic inflammatory diseases usually have a higher incidence and preva-
lence in females, there is much discussion about what would be the best therapeutic
strategy to be adopted during pregnancy, once treatment suspension may be asso-
ciated with “flares” of the underlying disease with deleterious effects for both the
mother and fetus, in addition to the fact that anti-TNF alpha present variables
degrees of placental transfer that can influence the immune response of the new-
born. Due to its molecular conformation devoid of the Fc region, which prevents
recognition by the FcRn receptor and consequently the active placental transfer,
certolizumab pegol was evaluated as a safe treatment option during pregnancy [34].
In 2017, a prospective pharmacokinetic study (CRIB study) was published
evaluating 16 patients with at least 30 weeks pregnancy who were treated with CZP
(three of them with CD) to assess the degree of placental transfer to the fetus via
the dosage of the serum level of the drug in the newborn plasma. Patients were
required to receive the last dose of CZP within a maximum of 35 days before
delivery to be included. It was observed that even with maternal plasma levels
within the therapeutic range of CZP, 13 of the 16 neonates had no detectable levels
of CZP in plasma and one shows minimum levels (0.09% concentration in maternal
plasma), which hardly had any clinical consequences [34]. In accordance with
previous studies, it was shown that CZP presents minimal to no placental transfer
even when used in the third trimester of pregnancy, unlike IFX, or ADA [35]. In the
same year, CRADLE study analyzed breast milk from 17 mothers who were treated
with the CZP (five of them with CD), showing that the drug concentration in breast
milk is minimal, with a relative dose transferred to the newborn well below the 10%
limit considered safe. Besides that, adverse events in patients exposed to CZP were
consistent with the known safety profile and newborns had an adverse event profile
that could be expected in an untreated population of similar age [36].
The CZP presents itself as another subcutaneously administered anti-TNF
option for CD with a suitable safety profile, especially in women in the reproductive
phase.
5. Golimumab (Simponi®)
Golimumab (GOLI), a fully humanized antibody anti-TNF alpha administered
subcutaneously, has been described as effective in induction of clinical response and
remission in ulcerative colitis in 2014, with the publication of PURSUIT-SC. This
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study combined the analysis of a phase 2 study (used to evaluate the appropriate
dose of induction therapy) and phase 3, demonstrating the superiority of the drug
over placebo. After determining the doses of 200/100 and 400/200 mg at the weeks
2 and 0 as the most appropriate induction regimen, 761 patients were randomized
1:1:1 to receive said regimens or placebo. At the end of 6 weeks, it was observed that
the groups randomized to receive the golimumab 200/100 and 400/200 mg had
better clinical response (51 and 54.9%, respectively) than placebo (30.3%;
p < 0.0001 for both comparisons), with no statistically significant differences
between the dosing schedules. Second, GOLI also demonstrated superiority to
placebo regarding clinical remission and mucosal healing [36].
Having 464 patients who responded to induction therapy with GOLI in previous
studies (PURSUIT-SC and PURSUIT-IV), PURSUIT-M evaluated the efficacy of the
drug in maintaining clinical response. Patients were randomized to receive 50,
100 mg, or placebo every 4 weeks and evaluated after 52 weeks of treatment at
week 54. As a result, 47% of patients receiving 50 mg and 49.7% of those who
received 100 mg had sustained clinical response, while 31.2% of those receiving
placebo had the same result (p = 0.01 and p < 0.001, respectively). Second, it was
observed that about 28% of the patients who had received 100 mg of golimumab
were in clinical remission and 42.4% in endoscopic remission, reinforcing its supe-
riority over placebo, in which 15.6% were in clinical remission (p = 0.004) and
26.4% achieved mucosal healing (p = 0.002) [37].
Thus, GOLI is presented as another subcutaneous anti-TNF therapy option for
ulcerative colitis. Due to its recent approval, more data on its long-term safety and
real life experience are needed (Table 1).
Main studies Objective Primary end
point
Results Conclusion
Infliximab
Cohort de
Targan
et al.
Assess the
efficacy of IFX in
inducing clinical
response in
patients with
moderate to
severe CD
Reduction of
CDAI ≥ 70 points
after 4 weeks of
single induction
dose
Placebo: 17% had
clinical response
IFX 5 mg/kg: 81% had
clinical response
IFX 10 mg/kg: 50%
had clinical response
IFX 20 mg/kg: 64%
had clinical response
A single induction
dose is superior to
placebo to induce
clinical response in
patients with
moderate to
severe CD
ACCENT I Assess the benefit
of maintenance
therapy with
infliximab in
patients with
active CD who
responded to a
single initial
infusion of
infliximab
Clinical remission
at week 30 (CDAI
< 150) and time
to loss of clinical
response by
week 54
Placebo: 21% in
remission at week 30;
mean time to loss of
response of 19 weeks
IFX 5 mg/kg at weeks
2 and 6, followed by
5 mg/kg every
8 weeks: 39% in
remission at week 30;
mean time to loss of
response of 38 weeks
IFX 5 mg/kg at weeks
2 and 6, followed by
10 mg/kg every 8
weeks: 45% in
remission at week 30;
mean time to loss of
response >54 weeks
Patients who
initially responded
to IFX are most
commonly in
remission at week
30 and 54, when a
dose of IFX is
maintained every 8
weeks
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Main studies Objective Primary end
point
Results Conclusion
ACCENT II Assess the
efficacy of
maintenance
treatment with
IFX in the closure
of fistulas in
patients with CD
having one or
more fistulas who
have responded to
the induction
therapy with IFX
Time to loss of
response during
54 weeks of
follow-up among
patients who had
a response at
week 14 and were
randomized
Placebo: mean time of
14 weeks to loss of
response
IFX: mean time to loss
of response of over 40
weeks
Patients with
penetrating CD
responding to
induction therapy
are more likely to
have a sustained
clinical response to
maintenance
therapy over a
54-week period
ACT I Assess the
efficacy of IFX in
induction and
maintenance
therapy in
patients with
moderate to
severe UC
Clinical response
at week 8 and
secondarily,
clinical remission
and mucosal
healing at weeks
8, 30, and 54
(among other
secondary end
points)
Clinical response at
week 8:
• Placebo: 37.2%
• IFX 5 mg/kg:
69.4%
• IFX 10 mg/kg:
61.5%
Clinical remission at
weeks 8, 30, and 54:
• Placebo: 14.9, 15.7,
and 16.5%
• IFX 5 mg/kg: 38.8,
33.9, and 34.7%
• IFX 10 mg/kg:
32, 36.9, and 34.4%
Mucosal healing at
weeks 8, 30, and 54:
• Placebo: 33.9, 24.8,
and 18.2%
• IFX 5 mg/kg: 62,
50.4, 45.5%
• IFX 10 mg/kg: 59%,
49.2, 46.7%
Patients with
moderate to severe
UC treated with IFX
at weeks 0, 2, and 6,
followed by
maintenance every 8
weeks, more
commonly have a
clinical response at
weeks 8, 30, and 54
than those who
received placebo
ACT II Assess the
efficacy of IFX in
induction and
maintenance
therapy in
patients with
moderate to
severe UC
Clinical response
at week 8 and
secondarily,
clinical remission
and mucosal
healing at weeks 8
and 30 (within
other secondary
end points)
Clinical response at
week 8:
• Placebo: 29.3%
• IFX 5 mg/kg:
64.5%
• IFX 10 mg/kg:
69.2%
Clinical remission at
weeks 8 and 30:
• Placebo: 5.7 and
10.6%
• IFX 5 mg/kg: 33.9
and 25.6%
• IFX 10 mg/kg: 27.5
and 35.8%
Mucosal healing at
weeks 8 and 30:
• Placebo 30.9 and
30.1%
• IFX 5 mg/kg: 60.3
and 46.3%
• IFX 10 mg/kg: 61.7
and 56.7%
Patients with
moderate to severe
UC treated with IFX
at weeks 0, 2, and 6,
followed by
maintenance every 8
weeks, more
commonly have a
clinical response at
weeks 8 and 30 than
those receiving
placebo
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Main studies Objective Primary end
point
Results Conclusion
SONIC Comparatively
assess the efficacy
of IFX
monotherapy,
AZA
monotherapy or
combined therapy
in patients with
moderate to
severe CD naïve
for biological
therapy
Clinical remission
free of corticoid
and, secondarily,
mucosal healing at
week 26
Clinical remission at
week 26:
• AZA: 30%
• IFX: 44.4%
• IFX + AZA:
56.8%
Mucosal healing at
week 26:
• AZA: 16.5%
• IFX: 30.1%
• IFX + AZA:
43.9%
Note: the observed
difference in mucosal
healing between the
IFX and IFX + AZA
groups was not
statistically
significant
Patients with
moderate to severe
CD treated with IFX
or IFX + AZA are
more likely to
achieve clinical
remission free of
corticosteroids than
those treated with
AZA alone
SUCCESS Comparatively
evaluate the
efficacy of IFX
monotherapy,
AZA
monotherapy, or
combined therapy
in patients with
moderate to
severe UC naïve
for biological
therapy
Clinical remission
free of corticoid
and secondarily
mucosal healing at
week 16
Clinical remission at
week 16:
• AZA: 23.7%
• IFX: 22.1%
• IFX + AZA:
39.7%
Mucosal healing at
week 16:
• AZA: 36.8%
• IFX: 54.6%
• IFX + AZA:
62.8%
Note: the difference
in mucosal healing
observed in IFX and
IFX + AZA groups
was not statistically
significant
Patients naive for
biological drugs
with UC treated
with combined
therapy are more
likely to achieve
clinical remission
than those treated
with monotherapy
drugs. Combined
therapy is associated
with better mucosal
healing rates when
compared to AZA
monotherapy
Adalimumab
CLASSIC I Assess ADA’s
efficacy in
inducing clinical
remission in
patients with
moderate to
severe CD naive
for biological
therapy
Clinical remission
at week 4 after
initial induction
therapy
Placebo: 12% of the
patients achieved
remission
ADA 40/20 mg: 18%
of the patients
achieved remission
18% (p = 0.36)
ADA 80/40 mg: 24%
of the patients
achieved remission
(p = 0.06)
ADA 160/80 mg: 36%
of the patients
achieved remission
(p = 0.001)
The ADA was
superior to placebo
in clinical remission
induction in patients
naive for biological
therapy with
moderate to severe
CD, with a dose of
160 mg at week 0
followed by 80 mg
at week 2 as the
recommended
regimen
CLASSIC II Assess the
efficacy and
safety of ADA in
maintenance
therapy in
Maintenance of
clinical remission
at week 56 in the
group of patients
randomized after
Placebo: 44% of the
patients had clinical
remission
ADA 40 mg every
other week: 79% of
ADA was more
effective than
placebo in maintain
remission after 56
follow-up
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Main studies Objective Primary end
point
Results Conclusion
patients with
moderate to
severe CD
responding to
induction therapy
the patients
maintained clinical
remission
ADA 40 mg weekly:
83% of the patients
maintained clinical
remission
ULTRA I Assess the
effectiveness of
ADA in clinical
remission
induction in
patients with
moderate to
severe UC naive
for biological
therapy
Clinical remission
at week 8 after
initial induction
therapy
Placebo: 9.2% of the
patients achieved
remission
ADA 80/40 mg: 10%
of the patients
achieved remission
(p = 0.833)
ADA 160/80 mg:
18.5% of the patients
reached remission
(p = 0.031)
The 160/80 mg dose
of ADA was
effective and safe in
inducing clinical
remission in patients
with moderate to
severe UC who
failed to corticoid or
immunosuppressive
therapy
ULTRA II Assess the
efficacy and
safety of ADA in
maintenance
therapy of
patients with
moderate to
severe UC
Maintenance of
clinical remission
at week 8 and
week 52 after
induction therapy
Placebo: 9.3% at week
8 and 8.5% at week 52
ADA: 16.5% at week 8
and 17.3% at week 52
ADA was effective
and safe in
maintaining clinical
remission in patients
with moderate to
severe UC who
failed to corticoid or
immunosuppressive
therapy
CHARM Assess the
efficacy and
safety of ADA in
maintenance
therapy in
patients with
moderate to
severe CD who
responded to
induction therapy
Percentage of
patients who
responded to
induction and
achieved clinical
remission at
weeks 26 and 56
Placebo: 17% at week
26 and 12% at week 56
ADA 40 mg every
other week: 40% at
week 26 and 36% at
week 56
ADA 40 mg weekly:
47% at week 26 and
41% at week 56
ADA maintenance
therapy in patients
with moderate to
severe CD who
responded to
induction therapy
was more effective
than placebo in
maintaining clinical
remission after 56
weeks of follow-up
GAIN Assess the
efficacy of ADA
in inducing
clinical remission
in patients with
moderate to
severe CD who
lost response or
were intolerant to
IFX
Clinical remission
at week 4 after
ADA induction
therapy
Placebo: 7% achieved
clinical remission at
week 4
ADA: 21% achieved
clinical remission in
week 4
ADA was more
effective than
placebo in inducing
clinical remission in
patients who lost or
were intolerant to
IFX
Certolizumab
pegol
PRECISE 2 Assess the
efficacy and
safety of CTZ in
inducing and
maintaining
Clinical response
rates in patients
with baseline CRP
≥10 mg/L at week
26
Placebo: 36% of
patients maintained
clinical response
CTZ: 62% of patients
Among patients who
responded to the
initial induction
dose, maintenance
of CTZ was more
12
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6. Comparative efficacy among anti-TNF agents
As stated above, the treatment of IBD with the advent of anti-TNF alpha and
more recently, other classes of biological drugs (anti-integrin, anti-IL 12/23 etc.) has
dramatically changed the natural history of the disease and the incidence of com-
plications. However, no head to head studies directly compared the efficacy of
different drugs. Lacking such data, the decision on which treatment regimen to be
used is mainly based on reported clinical experience, proposed algorithms by
clinical trials, patient preference and safety profile [38].
Although imperfect, indirect comparative analyses, such as network meta ana-
lyses are available evidence to assess efficacy of different drugs. In 2018, Singh
et al., through a systematic review and network meta-analysis, compared the effi-
cacy and safety of treatment with various biological drugs in CD in naive patients
for biological therapy (first-line therapy) and in patients previously tested with
some anti-TNF (second-line therapy). Comparing direct and indirect evidence from
18 randomized controlled trials (RCT’s) involving patients with moderate to severe
CD, it was observed that anti-TNF alpha, particularly IFX and ADA, were the
options with strongest evidence in the induction of clinical remission and response
as well as maintenance therapy. Ustekinumab and vedolizumab appear to have
similar efficacy in the first-line therapy and were not higher when compared to
IFX or ADA. The CZP at the standardized dose has been reported as inferior to the
other agents.
As second-line therapy (non-RCT using IFX or CZP as a second biological drug
was identified), in the specific subgroup of patients who lost response or were
intolerant to IFX, ADA seems to be superior compared to other agents. It is note-
worthy that, for patients with primary nonresponse to IFX, the effectiveness of the
ADA is uncertain, scenario in which ustekinumab seems to gain prominence. The
safety profile and the incidence of major adverse events were assessed in
Main studies Objective Primary end
point
Results Conclusion
response and
clinical remission
in patients with
moderate to
severe CD who
have responded to
induction therapy
maintained clinical
response
effective in
maintaining clinical
response than
placebo
Golimumab
PURSUIT Assess the
efficacy of
golimumab in
maintaining
clinical response
in patients with
moderate to
severe UC who
responded to
induction therapy
Maintenance of
clinical response
at week 54
Placebo: 31.2% of the
patients maintained
clinical response
Golimumab 50 mg:
47% of the patients
maintained clinical
response
Golimumabe 100 mg:
49.7% of the patients
maintained clinical
response
Golimumab
maintenance
therapy was more
effective than
placebo in
maintaining clinical
response after 54
weeks of follow-up
Table 1.
Main studies with Anti-TNF in inflammatory bowel disease.
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maintenance studies, not being seen clear superiority of one agent over the other,
although the risk of adverse events appears to be low to IFX and ustekinumab.
However, RCT’s involved in the analysis were not powered to determine this dif-
ference, so this result should be evaluated with caution. Vedolizumab, a gut-
selective anti-integrin, has not been clearly associated with an increased risk of
serious infections in RCT’s analysis and longitudinal cohorts. It is noteworthy that
the risk factors most associated with severe infections were concomitant use of
corticosteroids, narcotics and severe disease activity [38].
The same group published a meta-analysis evaluating the therapy in UC, where,
besides the efficacy of induction/maintenance of clinical remission and safety pro-
file of the drug, mucosal healing was also assessed. Combining direct and indirect
evidence of 14 RCT’s including 4212 patients with moderate to severe disease, the
group concluded that, as first-line therapy, all evaluated agents (IFX, ADA,
golimumab, and vedolizumab tofacitinibe) were superior to placebo, with IFX and
vedolizumab considered the most effective in the inducing of clinical remission and
mucosal healing. In general, ADA was considered the least effective agent for both
outcomes. Comparing IFX to ADA, data obtained favor IFX for induction of remis-
sion, however, as maintenance therapy, it appears to be no significant difference
between the two drugs [39]. Superiority of IFX can be associated with pharmacoki-
netics and bioavailability of the drug since its dosage is variable according to the
weight of the patient, unlike ADA with a fixed dose.
As second line therapy, tofacitinib (JAK-2 inhibitor) seems to be the best choice
for induction of remission and mucosal healing. A direct meta-analysis further
demonstrated that vedolizumab and ADA were not superior to placebo, conferring
a low level of evidence to indicate these drugs as a therapeutic alternative in this
scenario. Importantly however, the studies that assessed ADA included only
patients who lost response or were intolerant to IFX as part of the patients treated
with vedolizumab were not primary responders to IFX, which may be linked to a
specific population with a more aggressive form of the disease, disadvantaging
vedolizumab in this analysis. This information was not clear in studies with
tofacitinib and no study using IFX or golimumab as a second biological drug
was identified [39].
As a maintenance therapy, because of differences in the design of studies, RCT’s
involving IFX and ADA were considered separately from those involving
golimumab, vedolizumab, and tofacitinib. As stated earlier, IFX and ADA appear to
be equally effective in maintaining remission in naive treatment patients. The other
drugs were also superior to placebo in patients who responded to induction therapy
and did not seem to differ from each other. Regarding the safety profile, none of the
options was significantly worse compared to placebo in the incidence of adverse
events. Taking into account the incidence of serious infections, vedolizumab seems
to be the safer drug, since there was no difference compared to placebo, while
golimumab and tofacitinib were associated to higher risk of infection [39].
In an innovative way, the preliminary results of VARSITY, the first head to head
trial in IBD were presented in a specific event. It is a phase 3b double-dummy,
controlled and randomized trial, comparing ADA and vedolizumab in the treatment
of moderate to severe UC. With a total of 769 patients who had failed conventional
therapy (25% had been exposed to any anti-TNF), which were randomized into four
groups to receive vedolizumab vs. placebo or adalimumab vs. placebo, clinical remis-
sion (primary endpoint), and mucosal healing were assessed after 52 weeks. It has
been observed that patients treated with vedolizumab achieved clinical remission
rates of 31.3% and mucosal healing of 39.7%, significantly better than patients treated
with ADA (22.5% p = 0.0061 and 27.7% p = 0.0005, respectively), with no statisti-
cally significant difference in the incidence of infections and adverse events [40].
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7. Safety of anti-TNF agents
The use of TNF-alpha inhibitors and their combination with thiopurines has
proved to be more effective in controlling severe forms of CD and UC compared to
monotherapy [21, 22]. However the use of these drugs is associated to a higher risk
of adverse events, particularly infections and malignancies [41, 42].
The analysis of a cohort study involving a large number of patients [43], showed
a higher risk of serious and opportunistic infections in combination therapy than
with the use of anti-TNF or thiopurines alone. Comparing anti-TNF and thiopurines
in monotherapy, there was a higher incidence of serious infections and mycobacte-
rial infections associated with anti-TNF, however, there is no difference in the
incidence of opportunistic infections in general, since thiopurines were associated
with higher chance of viral opportunistic infections and anti-TNF to bacterial
infections. It is noteworthy that the results of a previous meta-analysis showed an
increased incidence of opportunistic infections by bacteria and mycobacteria in
patients treated with the combination therapy compared to monotherapy with anti-
TNF, inferring that the use of thiopurines adds an extra risk for developing infec-
tions [44]. There was a higher incidence of viral opportunistic infections when
combination therapy was compared to monotherapy with anti-TNF, but it did
not differ when compared to monotherapy with the thiopurines, suggesting that
the risk of this complication in the combination therapy is due to the use of
thiopurines [45].
It should be considered that not only therapeutic option is linked with a higher
risk of infectious complications, but also the patient’s age, disease severity, and
concomitant use of corticosteroids, all those associated with a worse outcome [46].
Classically, therapy with thiopurines is associated with an increased risk of
malignancy in patients with IBD, particularly non-Hodgkin’s lymphoma,
hepatosplenic lymphoma associated with EBV, cervical cancer associated with HPV,
urinary tract cancer, and non-melanoma skin cancer, both as monotherapy and in
combination therapy with an anti-TNF agent [42]. However, the association
between malignancy and anti-TNF alpha use remains uncertain. In prior
meta-analysis involving 21 placebo-controlled trials including more than 5000
patients with CD, treatment with anti-TNF was not associated with an increased
risk of cancer development [47].
Through the analysis of the TREAT™ Registry database, a prospective cohort
study that evaluated the outcomes of long-term treatment regimens in DC involv-
ing 6237 patients in with more than half used the IFX sometime in the follow-up, it
was found that, in general, the incidence of cancers (benign or malignant) was
similar between the group treated with IFX and with the other therapeutic options
[48]. In this study, age, disease duration and smoking were associated with
increased risk of cancer. In a more recent meta-analysis including 44 RCT’s and
more than 14,000 patients, and the incidence of malignancy as a secondary out-
come, it was not possible to conclude that the use of anti-TNF significantly affect
the risk of cancer. However, the data were scarce and periods of exposure and
follow-up were too short to allow conclusions [41]. The incidence of melanoma is
described as higher in patients with IBD in general, however, some studies suggest a
possible association with the use of anti-TNF [49] while others do not [50].
A recent French cohort gathered data from nearly 190,000 patients to assess risk
of lymphoma in patients with IBD that used azathioprine and/or anti-TNF agents.
Surprisingly, not only the use of thiopurines but also the use of anti-TNF
monotherapy was associated with a small but statistically significant increased risk
of lymphoma among patients exposed. The risk was greater in the combination
therapy than either drug alone [51].
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Other adverse events associated with anti-TNF therapy are described and should
also be remembered. Since there are reported the reactivation of tuberculosis and
hepatitis B virus after initiation of therapy, the pretreatment screening, in order to
guide the treatment of latent tuberculosis and prophylaxis with antiretroviral, is
indicated [52, 53]. In those patients who are in triple immunosuppression,
Pneumocystis jirovecii prophylaxis may be considered [54]. Infusion reactions (rela-
tively frequent), angioedema, anaphylaxis, lupus-like syndrome, psoriasis induced
by anti-TNF, eczematous lesions, demyelinating syndromes, and heart failure are
also described [54].
8. The role of therapeutic drug monitoring in the management of IBD
with anti-TNF agents
Although effective in the induction and maintenance of clinical remission and
mucosal healing, the therapeutic fail of anti-TNF is not uncommon in IBD, occur-
ring in patients which are considered as primary non-responders (10–40% approx-
imately) or lose the response in the first year of treatment (24–46%), and those who
have some adverse effect that lead to treatment interruption [24, 26]. An under-
standing of the factors involved in therapeutic failure, as the patient’s profile, the
presentation of the disease and the relationship between the concentration of the
drug and its interaction with the anti-drug antibodies (ADAbs), are useful tools to
guide the best strategy to be followed [55].
The concentration of drug in the site of action is directly linked to the magnitude
of the expected pharmacological response and its monitoring in specific scenarios
can assist in therapeutic decision. For example, the patient may experience an
inadequate response due to the low concentration of the drug secondary to
increased clearance, differing completely from one that has inadequate response
with therapeutic trough levels, suggesting mechanistic failure. In the first situation,
dose escalation can be effective, while the second would most benefit from
exchange to a medication with a distinct mechanism of action (Figure 2) [56].
Based on these assumptions, in 2017, the American Gastroenterological Associa-
tion has published a technical review on the role of therapeutic drug monitoring
(TDM) as an auxiliary tool in decision-making regarding treatment of IBD. In the
absence of adequate response, the dosage of the trough level of the drug has been
suggested as a first step (reactive approach): if the serum levels of anti-TNF are
within the therapeutic range, it is characterized the failure to the mechanism of
action and class exchange is possibly the best option. However, if serum levels are
below the appropriate, dosage of ADAbs can bring additional information: if they
are high, it is likely that the clearance of the drug is being immune-mediated, and it
is plausible the exchange of medication for a drug of the same class, besides the
association with immunomodulator. If the ADAbs level is undetectable or low, it is
likely that the clearance is increased due to mechanisms not immune-mediated,
such as severe inflammatory burden leading to rapid use of anti-TNF and/or exces-
sive loss in feces (indicated by hypoalbuminemia, CRP, and high fecal calprotectin),
which would allow the optimization of the dosage instead of changing the biological
agent. This strategy seems to be more effective than making decisions empirically,
despite the low level of evidence further described [56]. In patients with the disease
in remission, the dosage of the trough level and ADAbs as an auxiliary tool in
decision-making (proactive proposal) is still uncertain, with few studies that cor-
roborate its effectiveness, mainly regarding cost savings [57, 58].
In order to examine predictors of therapeutic failure to anti-TNF, PANTS study
has been recently published, a randomized clinical trial involving patients with
luminal CD naive for biological therapy who started treatment with IFX or ADA.
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Through regression logistic, it was identified that only low trough level in week 14
(IFX < 7 mg/L and ADA < 12 mg/L) was associated to the absence of primary
response. Obesity, smoking, hypoalbuminemia, high levels of inflammatory
markers, and the development of immunogenicity were associated with lower
serum levels of the drug. It was also observed that low levels at week 14 were
independently associated to non-clinical remission at week 54, and were associated
with increased formation of ADAbs. The combination with immunomodulators
(azathioprine or methotrexate) was associated with lower immunogenicity for both
IFX and ADA, and in the group of patients with IFX, combination therapy was
associated with higher clinical remission rate at week 54 compared to monotherapy
with IFX, unlike ADA, which was not more effective in maintaining remission
when associated with immunomodulators [55].
9. Final considerations
The initiation of therapy with tumor necrosis factor inhibitors certainly was a
milestone in the treatment of inflammatory bowel disease, drastically changing the
natural course of the disease and offering better quality of life to treated patients.
Figure 2.
anti TNF’s mechanisms of action are illustrated above. The inflammatory cascade triggered by TNFR is
disrupted by anti TNF-mediated direct blockade, which prevents binding of sTNF and tmTNF to specific
receptors. On the right are the results of tmTNF antagonization by the drug, which include cytotoxicity of the
CDC (complement – dependent cytotoxicity) or ADCC (antibody-dependent cellular cytotoxicity), as well as
reverse signaling via tmTNF. The pharmacokinetics-related are illustrated at the bottom of the image.
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With an acceptable safety profile, anti-TNF agents are excellent therapeutic options
in severe forms of the disease, with proven efficacy in both Crohn’s disease and
ulcerative colitis. The association with immunomodulators, particularly to
infliximab is associated with better outcomes. A lack of head to head trials that
compares the biological drugs limits the assessment of superiority among them to
indirect comparisons, making it crucial that such evidence come to light. Thera-
peutic drug monitoring seems to be useful tools in decision-making and can increase
the therapeutic success rates obtained. However, in the face of current evidence, it
has not yet been consolidated as a cost effective strategy.
Future perspectives involving anti-TNF agents include the development of new
molecules of this class. Currently, several new TNF-alpha inhibitors have been
studied in patients with CD. The DLX 105 (esbat Tech) is an anti-TNF antibody that
has been studied specifically in patients with fistulizing CD, trough a local injection
in a phase II trial (ClinicalTrials.gov NCT01624376), but no results are available to
date. Other two anti-TNF-alpha oral therapies, V565 (VHsquared) and OPRX-106
(Bio Protalix) are in the pipeline. The V565 is currently recruiting patients with
moderate to severely active CD to a phase II study (NCT02976129) after favorable
results in a phase Ib (NCT03010787). The OPRX-106 demonstrated efficacy in
clinical improvement of biomarkers in a phase II study of patients with mild to
moderate UC. It is worth to wait for these promising therapies, since the oral mode
of administration may be more convenient for some patients [59, 60].
In the era of the new mechanisms of action, this critical analysis consolidates the
anti-TNF agents as viable therapeutic options in the current IBD therapeutic
armamentarium.
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